

Barcelona, July 30, 2015

RESULTS OUTLINE: FIRST HALF OF 2015

In the first six months following the merger of Natraceutical and Reig Jofre

REIG JOFRE CLOSED THE FIRST HALF OF THE YEAR WITH GROWTH IN ALL ITS ECONOMIC INDICATORS

- Reig Jofre closed the first half of 2015 with sales of 81.5 M€ (+2.6%), EBITDA of 10.6 M€ (+5.5%) and net profit of 7.2 M€ (+16.6%).
- Non linear evolution of quarterly results throughout the year due to seasonality of part of the business. Compared to H1 2015 results, Reig Jofre expects to close the year with a total growth in EBITDA of around 15%.
- Debt repayment of 6.1 M€ in the first six months, with net financial debt at 10.5 M€, below one time EBITDA.
- The profitability increase and the subsequent generation of free cash flow estimated for 2015 will enable the company to continue accelerating its organic and non-organic growth plan for the coming years.
- Reig Jofre will conduct a reverse split in September with exchange ratio of 1x20, to increase the share stability, as agreed in its last Shareholders' General Meeting.

PRESENTATION OF RESULTS

Reig Jofre will hold at 11:30 am CET today, Thursday July 30, 2015, a presentation of results webcasted live.

Access to the conference through the link: <http://bit.ly/1O0NO9j>



In addition to the webcast site, the presentation document will be available a few minutes before the webcast on the CNMV website and in the "Investors/Presentations" section of the company site (www.reigjofre.com)

PROFIT AND LOSS ACCOUNT FOR THE FIRST HALF OF 2015

<i>(in euro)</i>	H1 2014 proforma	H1 2015 consolidated	Dif.
Turnover	79,446,149	81,493,618	2.6%
Cost of goods sold	-28,286,729	-29,915,983	
Gross margin	51,159,420	51,577,635	0.8%
Other operating income	-36,744	350,851	
Overheads	-20,253,276	-19,844,426	
R&D expenses	-2,824,417	-2,710,672	
Other operating expenses	-17,982,944	-18,757,331	
Depreciation and amortization	-2,694,988	-2,309,395	
Impairment and result on disposals	796,858	21,181	
Operating income	8,163,909	8,327,843	2.0%
Financial income	131,800	126,108	
Financial expenses	-491,700	-464,828	
Results from the disposal of financial instrumen	0	0	
Results from asset impairment	0	0	
Changes in fair value of financial assets	-10,238	-84,494	
Exchange differences	-58,808	317,372	
Equity in the results of subsidiaries	0	0	
Profit before taxes	7,734,963	8,222,001	6.3%
Income tax	-1,576,796	-1,043,660	
Net result	6,158,167	7,178,341	16.6%



BALANCE SHEET ON JUNE 30, 2015

(in euro)	30/06/2015	31/12/2014
ASSETS		
Non-current assets		
Goodwill	25,147,584	25,405,979
Other intangible assets	32,487,672	32,453,457
Property, plant and equipment	25,804,315	24,045,938
Non-current financial assets	9,926,045	9,962,273
Deferred tax assets	15,408,680	16,527,753
TOTAL NON-CURRENT ASSETS	108,774,296	108,395,400
Current assets		
Inventories	24,190,472	23,839,539
Trade and other receivables	32,360,529	29,870,526
Current tax assets	-	958,294
Other current financial assets	2,474,968	4,338,579
Other current assets	7,417,420	4,991,922
Cash and cash equivalents	8,350,856	8,349,509
TOTAL CURRENT ASSETS	74,794,245	72,348,369
TOTAL ASSETS	183,568,541	180,743,769
EQUITY AND LIABILITIES		
Equity		
Share capital	126,428,441	126,428,441
Reserves	(4,483,401)	(6,791,795)
Treasury shares	(4,901,950)	(4,901,950)
Interim dividend paid during the year	-	-
Profit attributable to the parent company	7,172,942	2,308,394
Exchange differences	870,465	1,057,767
Other comprehensive income for assets available for	43,331	43,331
Equity attributable to parent company	125,129,828	118,144,188
Non-controlling interests	32,917	27,516
TOTAL EQUITY	125,162,745	118,171,704
Non-current liabilities		
Capital grants	123,677	144,859
Provisions	1,874,368	969,762
Financial liabilities with credit institutions	5,166,643	5,805,594
Financial lease liabilities	6,124,862	6,408,506
Derivative financial instruments	419,457	419,457
Other financial liabilities	2,302,205	2,679,845
Deferred tax liabilities	3,578,785	4,829,060
TOTAL NON-CURRENT LIABILITIES	19,589,997	21,257,083
Current liabilities		
Provisions	418,606	419,308
Financial liabilities with credit institutions	5,064,179	10,181,723
Financial lease liabilities	583,011	596,388
Other financial liabilities	806,789	753,210
Trade and other payables	27,983,789	24,805,199
Tax assets and liabilities	1,117,974	1,426,954
Other current liabilities	2,841,451	3,132,200
TOTAL CURRENT LIABILITIES	38,815,799	41,314,982
TOTAL EQUITY AND LIABILITIES	183,568,541	180,743,769



About Reig Jofre

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the development, manufacture and marketing of own products (approximately 78% of sales) and one of specialized manufacturing for thirds (22% of sales). At its core activity, the company specializes in the development of prescription and non-prescription pharmaceutical products, injectable generics based on specialized technologies, medical devices, food supplements and cosmetics. The company directs its R&D to develop new indications and/or dosage forms of known active principles, generic medicines with a special focus on beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and food supplements as well as the development of new innovative molecules in partnership with start-ups and research centers.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 1,264,284,408

For further information

Media

Ricardo Franco

ATREVIA

Tel. +34 93 419 06 30

rfranco@atrevia.com

Investors and analysts

Gloria Folch

Head of Investor Relations

REIG JOFRE

Tel. (+34) 93 480 67 10

gloria.folch@reigjofre.com